Recently, in the randomized, double-blind, placebo-controlled clinical trial ASSAIL-MI (ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction), IL-6R inhibition with tocilizumab, a humanized anti–IL-6R monoclonal antibody, significantly attenuated inflammation and increased myocardial salvage in STEMI patients (6). This evidence concerns the gene IL6 and myocardial infarction.